Caraco Pharmaceutical Laboratories launches new eye drug

Caraco Pharmaceutical Laboratories, a developer of generic and private-label pharmaceuticals, has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the FDA for Sun Pharma's abbreviated new drug application for generic Acular ophthalmic solution on the first day following patent expiration.

This strength of ketorolac is therapeutically equivalent to Acular ophthalmic solution, 0.5%, from Allergan.

According to Caraco, ketorolac tromethamine ophthalmic solution is indicated for temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction.